FDA's Busy Week: Breakthrough Approvals for Pancreatic Cancer, Heart Risk, and Rare Blood Disorders

The FDA has greenlit a potential game-changer for one of the deadliest cancers: Revolution Medicines' Rasonque (daraxonrasib) is now approved for metastatic pancreatic cancer, a disease where five-year survival rates hover around 12%. The drug, which stunned researchers by nearly doubling survival times in earlier trials, represents a significant new weapon in oncology's arsenal. Endpoints News calls it a "landmark approval" that could reshape treatment paradigms.

##...